Drug companies and their trade groups employed 1,100 lobbyists and spent $155 million on federal lobbying efforts last year, according to the Center for Public Integrity. Topping any single company, PhRMA spent more than $18 million on lobbying last year and $104 million since 1998. Meanwhile, BIO spent $5.4 million last year and almost $35 million in the same nine-year span. Pfizer spent $12 million last year, more than any other firm. In comparison, Amgen spent over $10 million, Sanofi spent $6.7 million, and Merck spent just over $4 million...
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.